Empagliflozin reduced pulmonary vascular remodelling in lab cells and PAH rats, but in a phase IIa feasibility trial of 8 patients with idiopathic or heritable PAH, 12 weeks was tolerated with no change in NT-proBNP or 6MWD and RV ejection fraction fell (45% to 38%).
RCTn = 8
Yoshida et al. Empagliflozin Ameliorates Experimental Pulmonary Vascular Remodeling, but May Not Benefit Patients With Pulmonary Arterial Hypertension